Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teprotumumab plus Erlotinib in Advanced NSCLC
NCT00760929Phase 2Terminated
- Sponsor
- Roche
- Start
- Nov 2008
- Primary completion
- Jun 2010
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of teprotumumab in non-small cell lung cancer (NSCLC), sponsored by Roche. Started Nov 2008; status: terminated.
02
Drugs
teprotumumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00760929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00760929.